Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151744 (myocardial ischemia)
 31,282 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To a group of 24 subjects with hypercholesterolaemia (hyperlipoproteinaemia type II) for a period of three months the non-absorbable resin Colestid was administered in order to reduce levels of atherogenic lipids and lipoproteins. The Colestid doses were graded from 5 g in the first month to 10-15 g during the third month. Reduction of cholesterol levels and the LDL fraction was significant already during the first month of treatment. The greatest reduction of LDL cholesterol was 25% and of total cholesterol 15%. A favourable effect was recorded also in HDL cholesterol which increased. The rise of triacylglycerols was not significant. Differences in the serum lipid response or their fractions did not depend on sex (15 women, 9 men), the clinical symptomatology (IHD) or family-history of atherosclerosis or concurrent administration of fibrates (Lipanthyl in 7 patients). In view of the small doses the symptomatology of side-effects was poor. Four patients, however, did not complete three months of treatment. With regard to the economical aspect of therapy and the favourable effect of small doses the authors draw attention to this experience which can be used as a basis also when using combinations with other preparations of antihypercholesterolemic therapy in those patients where an adequate reduction of cholesterol and its LDL fraction is not achieved.
 ...
PMID:[Small doses of the resin Colestid in the treatment of hyperlipoproteinemia]. 200 12

We present results of investigation of fenofibrate in patients with ischemic heart disease and type 2 diabetes mellitus after myocardial revascularization at various terms of its administration. We have shown its efficacy in correction of diabetic dyslipidemia, positive influence on clinical status and long term result of coronary intervention. We have established that early (first 7 days) prescription of fenofibrate - Tricor to patients with ischemic heart disease and type 2 diabetes mellitus after myocardial revascularization lowers number of diagnostic coronary angiograms and repeat percutaneous coronary interventions by 11% during first year of follow-up.
 ...
PMID:[Possibilities of improvement of prognosis in patients with type 2 diabetes mellitus after coronary interventions]. 2187 80